title: T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment.
abstract: Peripheral T-cell lymphomas (PTCLs) are uncommon, heterogeneous, and aggressive non-Hodgkin's lymphomas. Despite progress in the last several years resulting in a deeper understanding of PTCL biology and pathogenesis, there is currently no accepted single standard of care for newly diagnosed patients, and for those with relapsed or refractory disease, prognosis is dismal. The National Cancer Institute convened a Clinical Trials Planning Meeting to advance the national clinical trial agenda in lymphoma. The objective was to identify unmet needs specific to five major lymphoma subtypes and develop strategies to address them. This consensus statement reviews recent advances in the molecular and genetic characterization of PTCL that may inform novel treatments, proposes strategies to test novel therapies in the relapsed setting with the hopes of rapid advancement into frontline trials, and underscores the need for the identification and development of active and biologically rational therapies to cure PTCL at higher rates, with iterative biomarker evaluation.
authors.affiliation: Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
authors.forename: Carla
authors.initials: C
authors.lastname: Casulo
authors.affiliation: Columbia University Medical Center, New York, NY, USA.
authors.forename: Owen
authors.initials: O
authors.lastname: O'Connor
authors.affiliation: Seattle Cancer Care Alliance, Seattle, WA, USA.
authors.forename: Andrei
authors.initials: A
authors.lastname: Shustov
authors.affiliation: University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Michelle
authors.initials: M
authors.lastname: Fanale
authors.affiliation: Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
authors.forename: Jonathan W
authors.initials: JW
authors.lastname: Friedberg
authors.affiliation: Department of Medicine, Weil Cornell University, New York, NY, USA.
authors.forename: John P
authors.initials: JP
authors.lastname: Leonard
authors.affiliation: Oncology Division, Washington University, St. Louis, MO, USA.
authors.forename: Brad S
authors.initials: BS
authors.lastname: Kahl
authors.affiliation: Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
authors.forename: Richard F
authors.initials: RF
authors.lastname: Little
authors.affiliation: University of California-Irvine Chao Family Comprehensive Cancer Center in Orange, CA, USA.
authors.forename: Lauren
authors.initials: L
authors.lastname: Pinter-Brown
authors.affiliation: Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
authors.forename: Ranjani
authors.initials: R
authors.lastname: Advani
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY , USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Horwitz
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D064096:Aurora Kinase A / Q000037:antagonists & inhibitors; D015415:Biomarkers; D035843:Biomedical Research; D002986:Clinical Trials as Topic; D032921:Consensus; D023381:Endpoint Determination; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors; D017730:Ki-1 Antigen / Q000037:antagonists & inhibitors; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics* / Q000378:metabolism; D058990:Molecular Targeted Therapy; D020380:Needs Assessment; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051076:Proto-Oncogene Proteins c-fyn / Q000037:antagonists & inhibitors; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D015398:Signal Transduction
chemical_list: D015415:Biomarkers; D017730:Ki-1 Antigen; D000081082:Phosphoinositide-3 Kinase Inhibitors; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases; D053612:Janus Kinases; D051076:Proto-Oncogene Proteins c-fyn; D064096:Aurora Kinase A